Press Releases May 28, 2026 08:30 AM

Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Aclaris Therapeutics to Engage with Investors at Jefferies 2026 Global Healthcare Conference

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
ACRS

Aclaris Therapeutics, a clinical-stage biopharmaceutical company focused on immuno-inflammatory diseases, announced its participation in the 2026 Jefferies Global Healthcare Conference where its CEO and leadership will present via a fireside chat and webcast. The event aims to communicate the company's progress and future plans to investors.

Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
ACRS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Aclaris Therapeutics will participate in a high-profile healthcare conference, signaling investor engagement.
  • The company is focused on developing novel treatments for immuno-inflammatory diseases.
  • A live webcast will allow broader access to the leadership's discussion, potentially enhancing transparency and investor confidence.

WAYNE, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday June 4, 2026, at 2:00 PM ET, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the 2026 Jefferies Global Healthcare Conference in New York, NY.

A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris website for at least 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.

Aclaris Therapeutics Contact:

Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com


Risks

  • As a clinical-stage biopharmaceutical company, product candidates are still in development and not yet commercialized, which carries inherent clinical and regulatory risks.
  • Market reception depends on the progress and success of the company’s R&D pipeline, which can be uncertain.
  • Broader economic or sector-specific market volatility may affect investor sentiment despite the company's engagement activities.

More from Press Releases

Cipher Digital Inc. Announces Proposed Offering of $810.0 Million of Senior Secured Notes Jun 8, 2026 Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal Jun 8, 2026 Global-e to Participate in Morgan Stanley US Financials Conference Jun 8, 2026 Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses Jun 8, 2026 Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives Jun 8, 2026